| Theme | How Can We Realize the Philosophy of Chronic Kidney Disease-Mineral and Bone Disorder? | |
|---|---|---|
| Title | CKD-MBD (CKD-mineral and bone disorder) and cardiovascular complication | |
| Publish Date | 2010/01 | |
| Author | Yukio Maruyama | Division of Kidney and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine |
| Author | Keitaro Yokoyama | Division of Kidney and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine |
| [ Summary ] | The definition of CKD-MBD (CKD-mineral and bone disorder) has spread around the world. One of the chief aims of treatment for this condition is to reduce the incidence of vascular calcification, especially when it has lead to cardiovascular complications. There are several guidelines, including the JSDT guideline. Management of serum phosphate, calcium, and parathyroid hormone levels are important for treatment. For the management of serum phosphate levels, regulation of phosphate intake and appropriate administration of phosphate binders are both essential. Cinacalcet hydrochloride and active vitamin D metabolites are key drugs for CKD-MBD treatment. Management of drug use to treat this condition is reviewed. | |